

22. An isolated polynucleotide encoding a polypeptide of Claim 21 or the full complement to the isolated polynucleotide.
23. The isolated polypeptide of claim 17, wherein the immunogenic fragment of (b) comprises at least 20 amino acids.
24. The isolated polypeptide of Claim 17 wherein the isolated polypeptide of (a) consists of one of SEQ ID NOs: 2 or 4.
25. An isolated polynucleotide encoding a polypeptide of Claim 24 or the full complement to the isolated polynucleotide.
26. A process for expressing the polynucleotide of Claim 25 comprising transforming a host cell with an expression vector comprising the polynucleotide and culturing the host cell under conditions sufficient for expression of the polynucleotide.
27. A fusion protein comprising the isolated polypeptide of Claim 17.
28. An isolated polynucleotide comprising the polynucleotide of one of SEQ ID NOs:1 or 3.
29. An isolated polynucleotide segment comprising a polynucleotide sequence or the full complement of the entire length of the polynucleotide sequence, wherein the polynucleotide sequence hybridizes to the full complement of one of SEQ ID NOs:1 or 3 minus the complement of any stop codon, wherein the hybridization conditions include incubation at 42 °C in a solution comprising: 50% formamide, 5x SSC (150mM NaCl, 15mM trisodium citrate), 50 mM sodium phosphate (pH7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20 micrograms/ml denatured, sheared salmon sperm DNA, followed by washing in 0.1x SSC at 65°C; and, wherein the polynucleotide sequence is identical to one of SEQ ID NOs:1 or 3 minus any terminal stop codon, except that, over the entire length corresponding to one of SEQ ID NOs:1 or 3 minus any terminal stop codon, n_n nucleotides are substituted, inserted or deleted, wherein n_n satisfies the following expression

$$n_n \leq x_n - (x_n \bullet y)$$

wherein x_n is the total number of nucleotides in one of SEQ ID NOs:1 or 3 minus any terminal stop codon, y is at least 0.95, and wherein any non-integer product of x_n and y is rounded down to the nearest integer before subtracting the product from x_n ; and wherein the polynucleotide sequence detects *Haemophilus influenzae*.

30. An expression vector comprising the isolated polynucleotide of Claim 18.
31. A host cell transformed with the expression vector of Claim 30.
32. A vaccine comprising the polypeptide of Claim 17 and a pharmaceutically acceptable carrier.
33. The vaccine of Claim 32, wherein the vaccine comprises at least one other *Haemophilus influenzae* antigen.
34. An antibody immunospecific for the polypeptide or immunogenic fragment of Claim 17.
35. A method for inducing an immune response in a mammal comprising administration of the polypeptide of Claim 17.
36. A method of diagnosing a *Haemophilus influenzae* infection, comprising identifying a polypeptide of Claim 17, or an antibody that is immunospecific for the polypeptide, present within a biological sample from an animal suspected of having such an infection.
37. A method for inducing an immune response in a mammal comprising administration of the isolated polynucleotide of Claim 18.
38. A therapeutic composition useful in treating humans with *Haemophilus influenzae* comprising at least one antibody directed against the polypeptide of claim 17 and a suitable pharmaceutical carrier.